At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 377 enrolled
Drug / intervention
Propranolol +1 moredrug
Likely dose
Propranolol 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
In Brief
A Phase 3 clinical trial evaluating Propranolol and Atenolol for Hemangioma. Completed, enrolled 377 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy of orally administered propranolol versus atenolol in the treatment of potentially disfiguring or functionally threatening IHs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemangioma
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedJan 2015
Primary CompletionSep 2018
TodayJul 2026
First PostedJan 19, 2015
Enrollment StartOct 1, 2013
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 11.5 years ago
Interventions
Propranololdrug
Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
Atenololdrug
Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.